WO1984001149A1 - Nouveau polypeptide et son utilisation - Google Patents

Nouveau polypeptide et son utilisation Download PDF

Info

Publication number
WO1984001149A1
WO1984001149A1 PCT/JP1982/000381 JP8200381W WO8401149A1 WO 1984001149 A1 WO1984001149 A1 WO 1984001149A1 JP 8200381 W JP8200381 W JP 8200381W WO 8401149 A1 WO8401149 A1 WO 8401149A1
Authority
WO
WIPO (PCT)
Prior art keywords
arg
antibody
add
ser
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1982/000381
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Kyozo Tsukamoto
Yuzo Ichimori
Mitsuhiro Wakimasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to PCT/JP1982/000381 priority Critical patent/WO1984001149A1/ja
Priority to US06/534,091 priority patent/US4681848A/en
Priority to AU19345/83A priority patent/AU564620B2/en
Priority to DK430583A priority patent/DK430583A/da
Priority to PH29569A priority patent/PH22559A/en
Priority to DE8383109402T priority patent/DE3362936D1/de
Priority to IE2215/83A priority patent/IE56003B1/en
Priority to IL69790A priority patent/IL69790A/xx
Priority to AT83109402T priority patent/ATE19088T1/de
Priority to NZ205666A priority patent/NZ205666A/en
Priority to EP83109402A priority patent/EP0103898B1/en
Priority to CA000437187A priority patent/CA1216807A/en
Priority to JP58176091A priority patent/JPS5980646A/ja
Priority to ZA837058A priority patent/ZA837058B/xx
Priority to KR1019830004438A priority patent/KR910001726B1/ko
Priority to JP59052244A priority patent/JPS6034994A/ja
Publication of WO1984001149A1 publication Critical patent/WO1984001149A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the e-t-in (IF if) is slaughtered when it is known that there are at least three types of eves of the anti-inflammatory type> ⁇ , ⁇ (see book-ch. 2 S ⁇ field,, 10 buys, 1380).
  • ⁇ see book-ch. 2 S ⁇ field,, 10 buys, 1380.
  • r3 ⁇ 47-in ( ⁇ -r) My-Gi3: 3 ⁇ , mainly ⁇ 3 ⁇ 4 It is also known as Hue P (Thein-Puen Beng Suen Yoonmu, Spoon: ⁇ -Sha,
  • ⁇ ⁇ is defined as the vegetative action of vegetative vegetation * #, €> plane * C Many creatures (Brapped, 35 Volume 71, 1 Buy, 130 Years; Oki, 58 Volume, 875 Buy, 1380) 3 Cultivation of Rogues The way to pass and the a3 ⁇ 4
  • * 3 ⁇ 4 ⁇ means that * Rickrona plant * for various IFH-r is not only important to establish molecular species correspondence, but also natural or arrested.
  • Parents and parents are ⁇ l l ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ .
  • the present invention is based on the novel polypeptide (I), its S-white ⁇ *, the newly synthesized hybridoma, the new * nota-n-aniline, and the method for producing them.
  • Nok-na is used for the purpose of the present invention. It is preferable to provide arg # Arg Ala Ser (Jin 2: is preferred), and U is mil # I r3 Arg is preferred, and po and peptide (I) are represented as ano groups.
  • the number is 1 S ⁇ 25.
  • the peptide can be produced "by hand" of the peptide peptide.
  • Solid phase synthesis method, 'Liquid phase synthesis method may be based on iMC, but liquid synthesis method may be a bottle association.
  • Peptide association ⁇ is, for example, “The Peptides No. 1 ⁇ (3 ⁇ S!), Schroder and Lu3 ⁇ 4ke »Academic Press, c York, USA, there is a - peptide synthesis ⁇ , AM et al., round ⁇ formula company (, 975 years>, there is ⁇ biochemistry Ryohida ⁇ , ⁇ 1 Spring, 207 purchases-400 purchases "Ya Akira Aya, Bunkyo Chemical Dojin Co., Ltd. (1917 ⁇ * C described, for example, azide method, copper ⁇ -ride method,» ⁇ hydrate method,
  • the peptide is one of two fragments that are bisected at any position of the peptide bond.
  • ⁇ ⁇ ((eg, meth, ⁇ ⁇ , w, ⁇ , t, t,-,-,-,-,-,-, p, p, p) ⁇ , ⁇ ia ⁇ ⁇ X ⁇ , , ⁇ ⁇ , ⁇ ⁇ 9 9 ⁇ ⁇ ⁇ ⁇ , ; ⁇ ⁇ ⁇ ⁇ t t t, t ⁇ t ⁇ ⁇ ⁇ * * ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ .
  • the guadino group of the agin is, for example, -t, t ⁇ , p-methoxybenzenespho-, carpopenzoki ⁇ , i, J-bo; Okipo, 4-Met key 2, 8-Mitzensho group, Pentamethine penzens, etc.! Will be done.
  • the Guadalmedina - Jinomoto is, acid ( «, Bae Nzeshisu; acid, door Enns * phosphate,:! It acid, etc. ⁇ acid):« 3 it may also be coercive ⁇ in ⁇ of
  • the hydroxyl group of threon can be protected by esterification or -monotiation, for example, by 7t.
  • suitable groups for esthetic treatment include aceti groups, lower akanoi groups, ⁇ , and nozoy groups * which are derived from alloy groups, pentoxy groups, and ti ir groups. 3 the group * etc. can be mentioned that - - the Chi of f suitable group,
  • the present butide kneading reaction is performed in the presence of a medium.
  • the porting medium can be selected from those that can be used in peptide conjugation reactions.
  • anhydrous 7 is a water-containing dimethicide. * ⁇ Adide, dimethis! * Oxide, virazine, kuhom, dioxane, dimethy, tet, hide-plan, drunk acid, IT- Suitable ⁇ -compounds such as methabi ⁇ 9 -don *
  • the reaction temperature is selected from the range of which is known to be the ⁇ butyto 'bond formation reaction * C can be used. It is usually about ⁇ 40 to about ⁇ 0, preferably about
  • the product has a protecting group after completion of the fiber-bonding reaction, it will be in a conventional manner.
  • conventional methods include, for example, conventional methods (eg, hydrogenation using a liquid such as PADIUM, the use of sodium metal in a liquid fan), ados ( ⁇ , tripo ⁇ -acid, In the presence of hydrogen peroxide, mensphonic acid, or a compound containing thiol, no, etc., the above-mentioned acids or a mixture of the above-mentioned acids can be mentioned.
  • the driving wheel is released using sheep, goat, rabbit, rabbit, rabbit, mouse, etc., using poitide (I) or protein complex.
  • the immunization method can be performed from subcutaneous, intra-abdominal, intra-static, intra-muscular, intra-dermal, etc. ]) Subcutaneous) preferably injected.
  • the immunity of the septum and the amount of immunity are highly variable, and the method of the species is starvation.
  • immunization is performed 2 to ⁇ times at 2 intervals, and ⁇ to 5 days after the final immunization, preferably A method that uses cells after 2-4 days is often used.
  • Immunization Jfc should be used as the amount of peptide at a time, mouse >> (I ⁇ & more, preferably ⁇ 0 * -30 ⁇ S: :: ? line, Ken ⁇ on Mai ⁇ in ⁇ above, also performs ⁇ experiments using the "flashing" ⁇ 2: and is desirable 3
  • the above-mentioned box S combination of the hepatic fibroid and the spheroid is, for example, the saturation of the excised mouse hypoxanthine-guan-phos * lipo ⁇ trans7Sasease deficiency (a thymidine kinase deficiency (f ⁇ ⁇ 3 ⁇ 4 ⁇ * ⁇ »» »» »» »» »» »» »» »» »» »» »» »» ⁇ »» ⁇ ⁇ ⁇ ⁇ ⁇ » ⁇ , Sendita
  • the fusion box sa is transited (Citf Penguin) using Hiboki Santin-Aminobutylin-Thymidine medium (EA Mi Neichia, No. 258 Spring, 435, 975), etc.
  • screening can be performed to determine whether or not the desired it body is produced. You can do it. In other words, at the meeting of t, first, the presence or absence of the t-body production by immunization as the ⁇ S3 »and the J peptide ⁇ ⁇
  • ⁇ ⁇ ⁇ ⁇ method can be used, but these methods can also use the seed wheat method.
  • An example of a preferred »titration, W Ru one way use the BIA * described C one by 3 cell B - Subi -; ⁇ of the carrier, for example Usagi anti Ma Usuimunogu ⁇ Brin body ⁇ method iC Therefore Kaburingu of *" C 2: After the IC assay, add the culture supernatant and mouse serum.
  • ⁇ is also hunger.
  • «Pimps egrets, mouse murginog Blind bodies were coupled according to the JC standard method, such as cell-beads. Add to the supernatant of the tomato and add to the mouse, and react for a certain period of time. After the reaction, wash the reaction well and add a certain amount of IF Iff-at.
  • IffH-r for example, a culture supernatant, which is induced by lectin and hobo EST from the human lectin ⁇ 2> * 1 and used as a culture supernatant, is used. After adding I ⁇ ir-1 rt, it reacts at a certain time ⁇ and constant S. After ⁇ , the activity of ⁇ ⁇ ⁇ ⁇ -r contained in i in o ⁇ in the reaction also leaks. I ⁇ ir of the antibody of interest in this way - and to measure the absorption ⁇ of r activity comes ffi 3
  • the antibody of the present invention also has the following properties.
  • I F Natsuichi r is made of purified i, which is, for example, Apige
  • amino acids, peptides, amino acids, activities, etc. are indicated by abbreviations *, and they are according to I USA C-I IJ BCCommisaia on Biological Joaenclature!
  • the ⁇ symbol is based on the resentment symbol * in that part, for example, 3 ⁇ 4Next tC.
  • amino acid * may have tc ⁇ isomer, but if it is specifically specified, it shall show L form.
  • Fig. I shows the melting pattern of the
  • t Ru 3 ⁇ 4 carbonochloridate ⁇ - 3 ⁇ 4 of Na ⁇ migration of H ⁇ 3 ⁇ 4 show ⁇
  • H-HtH c, 55.22 H, 7.07; V, 12.88; S, 3.M
  • the AcOEt layer was , 4 JtFaHG0 3 water, washed ⁇ 1 3 click phosphate solution, dried and lambda 3 Conegliano in S0 4, E - Te also to the ⁇ preparative addition, MeOH - E - Te by re itt ft 7t Yield 1 d5 f
  • Thrust c, 55.39! H, 7.17 ⁇ H, 13.34 ⁇ S, S.20
  • Serum dilution is fXS 300
  • ⁇ r-r activity is,,,, one _hol * body melting

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/JP1982/000381 1982-09-22 1982-09-22 Nouveau polypeptide et son utilisation Ceased WO1984001149A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
PCT/JP1982/000381 WO1984001149A1 (fr) 1982-09-22 1982-09-22 Nouveau polypeptide et son utilisation
US06/534,091 US4681848A (en) 1982-09-22 1983-09-20 Novel peptide and use thereof
AU19345/83A AU564620B2 (en) 1982-09-22 1983-09-21 Peptides and protein-peptide complexes
DK430583A DK430583A (da) 1982-09-22 1983-09-21 Polypeptider samt deres fremstilling og anvendelse
PH29569A PH22559A (en) 1982-09-22 1983-09-21 Monoclonal antibody and method for purifying human gamma interferon
DE8383109402T DE3362936D1 (en) 1982-09-22 1983-09-21 Novel peptide and use thereof
IE2215/83A IE56003B1 (en) 1982-09-22 1983-09-21 Novel peptide and use thereof
IL69790A IL69790A (en) 1982-09-22 1983-09-21 Peptides consisting of a sequence of human ifn-ypsilon and use thereof
AT83109402T ATE19088T1 (de) 1982-09-22 1983-09-21 Peptid und dessen verwendung.
NZ205666A NZ205666A (en) 1982-09-22 1983-09-21 Peptide derived from c-terminal region of human immune interferon,and conjugate with carrier protein;hybridomas and production of monoclonal antibodies against human immune interferon;purification or detection of human immune interferon
EP83109402A EP0103898B1 (en) 1982-09-22 1983-09-21 Novel peptide and use thereof
CA000437187A CA1216807A (en) 1982-09-22 1983-09-21 Peptide and use thereof
JP58176091A JPS5980646A (ja) 1982-09-22 1983-09-22 ヒトγ型インタ−フェロンの精製法
ZA837058A ZA837058B (en) 1982-09-22 1983-09-22 Peptide and use thereof
KR1019830004438A KR910001726B1 (ko) 1982-09-22 1983-09-22 펩티드의 제조방법
JP59052244A JPS6034994A (ja) 1982-09-22 1984-03-21 新規ポリペプチドおよびその用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1982/000381 WO1984001149A1 (fr) 1982-09-22 1982-09-22 Nouveau polypeptide et son utilisation

Publications (1)

Publication Number Publication Date
WO1984001149A1 true WO1984001149A1 (fr) 1984-03-29

Family

ID=13762331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1982/000381 Ceased WO1984001149A1 (fr) 1982-09-22 1982-09-22 Nouveau polypeptide et son utilisation

Country Status (3)

Country Link
JP (2) JPS5980646A (cg-RX-API-DMAC7.html)
WO (1) WO1984001149A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA837058B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004420A1 (fr) * 1984-03-29 1985-10-10 Takeda Chemical Industries, Ltd. Nouvel adn et son utilisation
JPH0653067B2 (ja) * 1984-09-11 1994-07-20 武田薬品工業株式会社 新規ハイブリドーマおよびその製造法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA814375B (en) * 1980-07-01 1982-07-28 Hoffmann La Roche Interferons and process for their preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mikolos Boanszky et al: "Peptide Synthesis (Second Edition)" (1976) John Wiley & Sons, Inc. (New York) *
Nature, Vol. 295, No. 11, 11. February. 1982 (11.02.1982) P. 503-508 *

Also Published As

Publication number Publication date
JPS5980646A (ja) 1984-05-10
ZA837058B (en) 1984-04-25
JPS6034994A (ja) 1985-02-22
JPS6234760B2 (cg-RX-API-DMAC7.html) 1987-07-28

Similar Documents

Publication Publication Date Title
JP4219339B2 (ja) 改変されたペプチドyyおよびそれらの結合体
ES2202409T3 (es) Preparacion de polieter con contenido en acido carboxilico y sustancias biologicamente activas derivadas.
ES2705714T3 (es) Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
US5728680A (en) Methods for normalizing numbers of lymphocytes
EP3524617B1 (en) Gla domains as therapeutic agents
JP2518911B2 (ja) c―fms癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
HUT52784A (en) Process for producing glycine derivatives and pharmaceutical compositions containing them as active components
ES2211877T3 (es) Linea celular linfoblastoide b humana que secreta un anticuerpo anti-gangliosido.
JPS60120900A (ja) Lhrhアゴニストとして有用なlhph 同族体ノナペプチドおよびデカペプチド
RU2003121231A (ru) Молчащие анти-cd28-антитела и их применение
BG98426A (bg) Пептиди с органо-защитна активност,метод за тяхното получаване и приложението им за лечение
CN104558119B (zh) Yap蛋白抑制多肽及其应用
Biskind et al. Atrophy of ovaries transplanted to the spleen in unilaterally castrated rats; proliferative changes following subsequent removal of intact ovary
CN106046121B (zh) 一种靶向fap的抗血管生成肽z-gp-v1及其应用
JPH02500517A (ja) ペプチド化合物
CN105949282A (zh) 一种靶向fap的抗血管生成肽z-gp-v2及其应用
JPH10501813A (ja) 腫瘍処置のための組成物および方法
TWI300414B (en) Modified peptide yy and conjugates thereof
JPH01501683A (ja) ファクター8の高収量生産法
Templeton et al. Complete foldback transposable elements encode a novel protein found in Drosophila melanogaster.
ES2377002T3 (es) Conjugados covalentes entre los endoperóxidos relacionados con la artemisinina y las proteínas transportadoras de hierro y procedimientos de utilización
CN112094317B (zh) His-Gly-Lys修饰的甲氨蝶呤,其合成,抗转移活性和应用
CN116333046B (zh) 八肽、环八肽及衍生物、制备方法以及在制备抗肿瘤药物中的应用
JP2008502323A5 (cg-RX-API-DMAC7.html)
CN108611371A (zh) 乳汁中表达gp5-m蛋白的奶山羊乳腺生物反应器的制备方法

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): MC